(Springfield, MA) – Massachusetts Mutual Life Insurance Company (MassMutual) announced today it has elected three new members to its Board of Directors: Isabella D. (Bella) Goren, former Chief Financial Officer of American Airlines, Inc. and AMR Corporation; Mark T. Bertolini, Chairman, Chief Executive Officer and President of Aetna Inc., and Jeffrey M. Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex Pharmaceuticals Incorporated. With the three additions, MassMutual will have 15 Board of Director members.
“I am very pleased to welcome Mark Bertolini, Bella Goren and Dr. Jeffrey Leiden to MassMutual’s Board of Directors,” said Roger Crandall, Chairman, President and CEO. “These three outstanding leaders, who bring with them more than 90 years of business and academic acumen and demonstrated leadership, are extremely valuable additions to our Board. MassMutual’s Board of Directors is one of the cornerstones upon which we have built and carried out our strong corporate governance oversight, and the Board’s longstanding reputation for integrity is clearly one of our company’s most valuable assets. Importantly, the appointments continue our strong progress in diversifying our Board, and underscore our unwavering commitment to include the broadest possible range of cultures, backgrounds, experiences and perspectives.”
Isabella D. (Bella) Goren – Ms. Goren is a former CFO of American Airlines, Inc. and AMR Corporation, a position she held from 2010-2013. She became a member of the Executive Committee in 2006, with her appointment as American’s Senior Vice President, Customer Relationship Marketing. Ms. Goren joined the company in 1986 as a Financial Analyst, and held roles of progressively greater responsibility with the company, including management positions in Human Resources and Revenue Management, Director of Investor Relations, Vice President of Asia/Pacific operations and President of AMR Services, among others. She began her career in 1983 as a Chemical Engineer for DuPont. Ms. Goren’s appointment is effective December 9, 2014.
Ms. Goren currently serves on the Board of Directors of both Gap Inc. and LyondellBasell Industries N.V., and is a Member of the Executive Board of Southern Methodist University’s School of Engineering.
She graduated with a Bachelor of Science in Chemical Engineering from the University of Texas, and earned her Master of Business Administration from Southern Methodist University.
Mark T. Bertolini – Mr. Bertolini has held several executive leadership roles with Aetna since joining the company in 2003 as Senior Vice President, Specialty Products. He was named President in 2007, President and CEO in 2010, and assumed his current role in 2011. From 1999-2003, he served in several leadership roles with Cigna Healthcare, Inc., and, prior to that, was for five years Executive Vice President with NYLCare Health Plans Inc. Mr. Bertolini began his career in 1985 as Director of Business Development for SelectCare, Inc. Mr. Bertolini’s appointment is effective February 10, 2015.
Mr. Bertolini currently serves on Aetna’s Board of Directors, and is affiliated with several nonprofit entities, including Hole in the Wall Gang Camp, Inc., Fidelco Guide Dog Foundation Inc., and the National Gay & Lesbian Chamber of Commerce.
Mr. Bertolini holds a Bachelor of Science in Business Administration from Wayne State University, and earned his Master of Business Administration from Cornell University.
Jeffrey M. Leiden, M.D., Ph.D. – Dr. Leiden is currently Chairman, President and CEO of Vertex Pharmaceuticals Incorporated, a position he has held since 2012. Prior to Vertex, from 2006-2012, Dr. Leiden was with Clarus Ventures, most recently as a Managing Director. From 2000-2006 he served as President and COO of Abbott Laboratories, Inc. where he was responsible for running the company’s Pharmaceutical Products Division. Dr. Leiden’s appointment is effective February 10, 2015.
Dr. Leiden has also held various leadership roles within the academic and medical communities, including positions with the Harvard University School of Public Health and the Harvard Medical School, the University of Chicago Hospitals & Health Systems, Pritzker School of Medicine, the University of Michigan Medical School and Brigham and Women’s Hospital. He currently serves on the Boards of Vertex Pharmaceuticals, Quest Diagnostics and Brigham and Women’s Hospital. He formerly served on a number of corporate boards, including Abbott Laboratories, Millennium Pharmaceuticals, Inc., Shire PLC, TAP Pharmaceutical Products, Inc., TyRx Pharma, Inc., and Catabasis Pharmaceuticals.
Dr. Leiden is a graduate of the University of Chicago with a Bachelor of Science in Biological Sciences, where he also earned his M.D. and Ph.D.
Founded in 1851, MassMutual is a leading mutual life insurance company that is run for the benefit of its members and participating policyowners. The company has a long history of financial strength and strong performance, and although dividends are not guaranteed, MassMutual has paid dividends to eligible participating policyowners consistently since the 1860s. With whole life insurance as its foundation, MassMutual provides products to help meet the financial needs of clients, such as life insurance, disability income insurance, long term care insurance, retirement/401(k) plan services, and annuities. In addition, the company’s strong and growing network of financial professionals helps clients make good financial decisions for the long-term.
MassMutual Financial Group is a marketing name for Massachusetts Mutual Life Insurance Company (MassMutual) and its affiliated companies and sales representatives. MassMutual is headquartered in Springfield, Massachusetts and its major affiliates include: Babson Capital Management LLC; Baring Asset Management Limited; Cornerstone Real Estate Advisers LLC; The First Mercantile Trust Company; MassMutual International LLC; MML Investors Services, LLC, Member FINRA and SIPC; OppenheimerFunds, Inc.; and The MassMutual Trust Company, FSB.